Abstract: The present invention relates to topical pharmaceutical compositions for treatment or prophylaxis of onychomycosis, and other fungal conditions caused by Trichophyton rubrum and/or Trichophyton mentagrophytes, comprising an effective amount of an amine-based anti-fungal compound, such as terbinafine or a pharmaceutically acceptable salt thereof, and monocaprin, in certain proportions.

Abstract: The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: a) a discontinuous oil phase; b) a continuous aqueous phase comprising water; c) a thickening agent; d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; e) a pharmaceutically acceptable active agent; and f) optionally a dermatologically acceptable excipient. In one embodiment, the composition, in use, has a water vapor transmission rate of less than or about 75 g·m?2·hr?1 measured in vitro using the modWVTR test methodology.

Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.

Abstract: The present invention is directed to a novel combination of excipients with an active ingredient, such as Benzoyl Peroxide based (BPO) which is subject to degradation. In one embodiment the invention is a topical pharmaceutical or cosmetic cleanser composition comprising benzoyl peroxide present in an amount from about 2.0 to about 20% w/w; water, at least one anionic surfactant which is a alkylpolyglucoside (AG) derivative surfactant; at least one humectant, a thickening agent, and optionally at least one dermatologically acceptable excipient.

Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.

Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.

Abstract: The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: a) a discontinuous oil phase; b) a continuous aqueous phase comprising water; c) a thickening agent; d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; e) a pharmaceutically acceptable active agent; and f) optionally a dermatologically acceptable excipient. In one embodiment, the composition, in use, has a water vapor transmission rate of less than or about 75 g·m?2·hr?1 measured in vitro using the modWVTR test methodology.

Abstract: A polymeric composite coating includes a drug release retardant polymer matrix, and pH-responsive nanoparticulate pore former. The pH-responsive pore formers function to modulate the permeability of the coating in response to pH changes which can compensate any changes in drug solubility with negligible leaching of the pore formers. The pH-responsive nanoparticulate pore formers may also function as alcohol-resistant component to the overall composite coating to resist increased solubility and permeability in presence of alcohol at 40% ethanol concentration in aqueous media. In one embodiment, the drug release retardant polymer is made of cellulose derivatives.

Abstract: The present invention is directed to a novel combination of excipients with an active ingredient, such as Benzoyl Peroxide based (BPO) which is subject to degradation. In one embodiment the invention is a topical pharmaceutical or cosmetic cleanser composition comprising benzoyl peroxide present in an amount from about 2.0 to about 20% w/w; water, at least one anionic surfactant which is a alkylpolyglucoside (AG) derivative surfactant; at least one humectant, a thickening agent, and optionally at least one dermatologically acceptable excipient.

Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.